Journal of Traumatic Stress Disorders & Treatment

Short Communication A SCITECHNOL JOURNAL

Neurological Manifestations of COVID-19: Insights into Neuropatho genesis and Long-Term Effects

Caao Fei*

Department of Clinical Neuropsychology, University of Southern California, United States

***Corresponding author:** Caao Fei, Department of Clinical Neuropsychology, University of Southern California, United States, E-mail: feio@usc.edu

Citation: Fei C (2024) Neurological Manifestations of COVID-19: Insights into Neuropathogenesis and Long-Term Effects. J Trauma Stress Disor Treat 13(2): 396

Received: 10-Apr-2024, Manuscript No. JTSDT-24-131961; **Editor assigned:** 11-Apr-2024, PreQC No. JTSDT-24-131961 (PQ); **Reviewed:** 23-Apr-2024, QC No. JTSDT-24-131961; **Revised:** 28-Apr-2024, Manuscript No. JTSDT-24-131961 (R); **Published:** 30-Apr-2024, DOI:10.4172/2324-8947.100396

Introduction

Since the emergence of the novel coronavirus, SARS-CoV-2, in late 2019, the global medical community has witnessed a diverse array of clinical manifestations associated with COVID-19, ranging from respiratory symptoms to multi-organ dysfunction. Increasing evidence suggests that SARS-CoV-2 can also affect the central nervous system (CNS), leading to a spectrum of neurological manifestations. In this article, we explore the neurological manifestations of COVID-19, elucidate the underlying neuropathogenesis, and discuss the long-term implications of CNS involvement in COVID-19 survivors [1].

Encephalopathy and Delirium: COVID-19 patients may present with acute encephalopathy or delirium, characterized by altered consciousness, confusion, disorientation, and cognitive impairment. Encephalopathy may result from direct viral invasion of the CNS, systemic inflammation, hypoxia, metabolic disturbances, or drug toxicity [2].

Stroke and Cerebrovascular Events: SARS-CoV-2 infection is associated with an increased risk of stroke and cerebrovascular events, particularly in severe cases. Ischemic strokes, hemorrhagic strokes, and cerebral venous thrombosis have been reported in COVID-19 patients, possibly due to hypercoagulability, endothelial dysfunction, and vasculitis [3].

Guillain-Barré Syndrome (GBS): GBS, a rare autoimmune disorder characterized by acute-onset weakness and sensory disturbances, has been reported in COVID-19 patients, suggesting a potential post-infectious immune-mediated mechanism. GBS may occur following viral infections, including SARS-CoV-2, due to molecular mimicry or dysregulated immune responses [4].

Anosmia and Ageusia: Anosmia (loss of smell) and ageusia (loss of taste) are common neurological symptoms observed in COVID-19 patients, often preceding respiratory symptoms. These sensory disturbances may result from direct viral invasion of olfactory and gustatory epithelial cells or secondary inflammation of the olfactory bulb and taste receptors [5].

Neuropsychiatric Symptoms: COVID-19 patients may experience a range of neuropsychiatric symptoms, including anxiety, depression, insomnia, and post-traumatic stress disorder (PTSD). These symptoms may be triggered by the psychological stress of the pandemic, social isolation, fear of contagion, or direct effects of the virus on the CNS [6].

Direct Viral Invasion: SARS-CoV-2 can enter the CNS through several routes, including hematogenous spread across the blood-brain barrier, retrograde neuronal transport along olfactory and trigeminal nerves, or invasion of endothelial cells and pericytes in cerebral blood vessels. Neuroinflammation: Systemic inflammation and cytokine release associated with COVID-19 can trigger neuroinflammatory responses in the CNS, leading to blood-brain barrier dysfunction, glial activation, and release of pro-inflammatory cytokines, chemokines, and reactive oxygen species [7].

Coagulopathy and Thrombosis: COVID-19-induced hypercoagulability and endothelial dysfunction may predispose to microvascular thrombosis, ischemia, and infarction in the brain, contributing to stroke and cerebrovascular events. Immune Dysregulation: Dysregulated immune responses, including cytokine storms, autoimmunity, and antibody-mediated pathology, may contribute to autoimmune-mediated neurological disorders such as GBS and acute disseminated encephalomyelitis (ADEM) in COVID-19 patients [8].

Emerging evidence suggests that some COVID-19 survivors may experience persistent neurological symptoms and long-term cognitive impairment, collectively known as “long COVID” or post-acute sequelae of SARS-CoV-2 infection (PASC). Long-term neurological effects of COVID-19 may include: Cognitive Dysfunction: Longitudinal studies have reported cognitive deficits, including memory impairment, executive dysfunction, and attentional deficits, in COVID-19 survivors months after acute infection. The underlying mechanisms of cognitive dysfunction in long COVID are not fully understood but may involve neuroinflammation, neurodegeneration, and white matter abnormalities [9].

Fatigue and Sleep Disturbances: Chronic fatigue, sleep disturbances, and daytime somnolence are common complaints among long COVID patients, which may be attributable to persistent inflammation, dysregulated immune responses, and alterations in neuroendocrine pathways. Neuropsychiatric Sequelae: Long COVID patients may also experience neuropsychiatric sequelae, including depression, anxiety, PTSD, and cognitive-emotional disturbances, which can significantly impair quality of life and functional recovery. Post-Viral Syndromes: Long COVID shares similarities with other

post-viral syndromes, such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), fibromyalgia, and post-infectious autoimmune disorders, suggesting overlapping pathophysiological mechanisms and potential treatment strategies [10].

Conclusion

The neurological manifestations of COVID-19 represent a significant clinical challenge, with implications for patient care, prognosis, and long-term outcomes. Understanding the neuropathogenesis of COVID-19 and its impact on the CNS is essential for developing effective strategies for prevention, diagnosis, and management of neurological complications in COVID-19 patients. Moreover, ongoing research into the long-term effects of SARS-CoV-2 infection and post-acute sequelae of COVID-19 is critical for providing comprehensive care and support for individuals affected by this unprecedented global pandemic.

References

1. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, et al (2020) Neurological associations of COVID-19. Lancet Neurol, 19(9):767-83.
2. Mao L, Jin H, Wang M, Hu Y, Chen S, et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol, 77(6):683-90.
3. Onteddu SR, Nalleballe K, Sharma R, Brown AT (2020) Underutilization of health care for strokes during the COVID-19 outbreak. Int J Stroke, 15(5):NP9-10.
4. Varatharaj A, Thomas N, Ellul MA, Davies NW, Pollak TA, et al (2020) Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psych, 7(10):875-82.
5. Taquet M, Luciano S, Geddes JR, Harrison PJ (2021) Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psych, 8(2):130-40.
6. Puccioni-Sohler M, Poton AR, Franklin M, Silva SJ, Brindeiro R. Current evidence of neurological features, diagnosis, and neuropathogenesis associated with COVID-19. Revista da Sociedade Brasileira de Medicina Tropical. 2020;53:e20200477.
7. Stefano GB, Büttiker P, Weissenberger S, Ptacek R, Wang F, et al. Biomedical perspectives of acute and chronic neurological and neuropsychiatric sequelae of COVID-19. Curr Neuropharm. 2022;20(6):1229.
8. Wang F, Kream RM, Stefano GB. Long-term respiratory and neurological sequelae of COVID-19. Med Sci Monit Int J Exp Clin Res. 2020;26:e928996-1.
9. Septyaningtrias DE, Susilowati R. Neurological involvement of COVID-19: from neuroinvasion and neuroimmune crosstalk to long-term consequences. Rev Neuro. 2021;32(4):427-42.
10. Balcom EF, Nath A, Power C. Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease. Brain. 2021;144(12):3576-88.